Technical / White Paper

Increasing the Bioavailability of Oncology Drugs

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This content is provided by Lonza Small Molecules, and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com

Increasing the Bioavailability of Oncology Drugs

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract. Most crystalline TKI drugs have pH-dependent solubility that affects their bioavailability in an oral dosage form.

This white paper outlines the challenges associated with pH-dependent solubility for oral TKI drugs and reviews how leveraging ASD formulation can help create more effective, patient-friendly drug products.

Latest content from Lonza Small Molecules

show more

Lonza de-risks drug development through PBPK

Paid for and in partnership with Lonza Small Molecules

The opportunity to de-risk drug development through PBPK

No company wants to progress a molecule through to the clinic only to suffer a bad readout. PBPK modeling services allow companies to predict what absorption challenges may arise in trials, and plan ways to mitigate them.

Show more

Related resources from Lonza Small Molecules

Supplier info centre